FGEN vs MCO · rev $29.6M vs P/E 33, rev $4.26B
FibroGen Inc (FGEN) versus Moodys Corporation (MCO) — a side-by-side from cached financials, not a winner call.
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ.
Moodys Corporation (MCO) is a financial data & stock exchanges company listed on NYSE.
Latest reported FGEN revenue for 2024-12-31 was $29.6M. Net income was -$47.6M. Revenue was down 36.7% from 2023-12-31 to 2024-12-31. FGEN currently screens at market cap $39.3M.
Latest reported MCO revenue for 2026-06-30 was $4.26B. Net income was $1.54B. MCO currently screens at market cap $79.69B and trailing P/E 32.7.
FGEN currently screens at market cap $39.3M. MCO currently screens at market cap $79.69B and trailing P/E 32.7.
Not investment advice. Open the FGEN and MCO stock pages for the full models.
Not investment advice.